Tin tức & Cập nhật

STELLAR trial offers hope for rare heart-lung disorder
STELLAR trial offers hope for rare heart-lung disorder
13 Mar 2023 bởiAudrey Abella

The phase III STELLAR trial lives up to its name, delivering stellar results and offering hope for patients with pulmonary arterial hypertension (PAH), a rare, progressive, life-threatening disorder affecting the heart and lungs, by adding sotatercept – a novel first-in-class activin signalling inhibitor – to background therapy.

STELLAR trial offers hope for rare heart-lung disorder
13 Mar 2023
BP awareness, drug adherence help prevent death, morbidity in stroke patients
BP awareness, drug adherence help prevent death, morbidity in stroke patients
10 Mar 2023
Longer time in BP target protects against adverse cardiovascular events in diabetes
Longer time in BP target protects against adverse cardiovascular events in diabetes
08 Mar 2023

For patients with hypertension and diabetes, longer time spent in blood pressure (BP) target range helps lower the risk of cardiovascular disease, according to a study.

Longer time in BP target protects against adverse cardiovascular events in diabetes
08 Mar 2023
GLP-1 RAs vs SGLT2 inhibitors: What are the comparative risks of ischaemic stroke and incident AF?
GLP-1 RAs vs SGLT2 inhibitors: What are the comparative risks of ischaemic stroke and incident AF?
08 Mar 2023 bởiNatalia Reoutova

A population-based retrospective study of Hong Kong patients with type 2 diabetes (T2D) finds that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a lower risk of ischaemic stroke, while use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a lower risk of atrial fibrillation (AF).

GLP-1 RAs vs SGLT2 inhibitors: What are the comparative risks of ischaemic stroke and incident AF?
08 Mar 2023